B. Riley Weighs in on Immunic's Q3 Earnings (NASDAQ:IMUX)

Key Points

• B. Riley has revised down Immunic's Q3 2025 earnings per share (EPS) estimate from ($0.12) to ($0.21), maintaining a "Buy" rating with a price target of $5.00.
• Immunic recently reported a quarterly EPS of ($0.20), missing analysts' expectations of ($0.18) by ($0.02).
• Institutional investors now own 51.82% of Immunic's stock, indicating significant interest from larger investment firms.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at B. Riley dropped their Q3 2025 earnings per share (EPS) estimates for Immunic in a note issued to investors on Monday, September 1st. B. Riley analyst W. Wood now forecasts that the company will post earnings of ($0.21) per share for the quarter, down from their prior forecast of ($0.12). B. Riley has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.78) EPS and FY2026 earnings at ($0.36) EPS.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02).

IMUX has been the subject of a number of other research reports. William Blair reaffirmed an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. Based on data from MarketBeat, Immunic currently has an average rating of "Buy" and a consensus price target of $7.50.

Immunic Stock Up 0.7%

IMUX stock opened at $0.80 on Thursday. The company has a market cap of $79.38 million, a PE ratio of -0.86 and a beta of 1.44. The business has a 50-day simple moving average of $0.88 and a 200 day simple moving average of $0.96. Immunic has a 52 week low of $0.56 and a 52 week high of $2.11.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Bridgeway Capital Management LLC raised its stake in Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after acquiring an additional 22,200 shares in the last quarter. Focus Partners Wealth raised its stake in Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after acquiring an additional 23,610 shares in the last quarter. Barclays PLC acquired a new position in Immunic during the fourth quarter worth about $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Immunic by 90.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after purchasing an additional 96,894 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.